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T HE PATHOGENESIS of hyperacute 
organ rejection involves a specific ini-
tiating immunologic reaction that consists of 
antibody-mediated injury directed against 
antigens on the vascular endothelium of trans-
planted organs. I,2 This unleashes a very 
intense and complex nonspecific effector cas-
cade that involves most of the classic mediator 
systems of the acute inflammatory process.3 
The final response can be described as a 
failure or breakdown of the microvasculature 
that results in intravascular coagulation and 
ischemic necrosis of the organ, with a charac-
teristic pathological appearance.4•6 
Immunosuppressive agents, such as cyclo-
sporine or FK-506, which inhibit classic cell-
mediated rejection, should therefore not be 
expected to have a significant and consistent 
effect on hyperacute rejection when used 
alone. However, one new potential approach 
for controlling the effector cascade of hyper-
acute rejection by pharmacological interven-
tion exploits the role of acetyl glycerol ether 
phosphorylcholine or platelet-activating fac-
tor (PAF) as a central candidate in the overall 
evolution of this inflammatory process.7,s 
There is now clear evidence that establishes 
the candidacy of PAF as a key biologic media-
tor in the pathogenesis of antibody-mediated 
hyperacute allograft rejection.9- 11 Therefore, 
inhibition of PAF-induced reactions offers a 
potentially significant therapeutic approach 
to this entity. 
SRI 63-441 is currently the most potent 
and specific PAF receptor antagonist avail-
able. 12 Our recent studies represent the first 
known report to describe the therapeutic effi-
cacy of a PAF antagonist (SRI 63-441) in any 
model of hyperacute rejection. 13 The combi-
nation of SRI 63-441 with either prostacyclin 
or prostaglandin EI resulted in a six- to nine-
fold increase in kidney survival and a three- to 
30-fold increase in urine output when com-
pared with control animals in a pig-to-dog 
renal xenograft model. 13 Furthermore, subse-
quent studies have demonstrated that a single 
bolus injection of SRI 63-441 alone, before 
revascularization, could significantly improve 
rat cardiac allograft survival in sensitized 
recipients (unpublished results). Histological 
evaluation of hearts that had functioned nor-
mally and then ceased at three and four days 
demonstrated a very aggressive acute cellular 
rejection compared with a classic picture of 
hyperacute cardiac rejection consisting of 
myonecrosis and intravascular coagulation in 
control rats. These findings suggested that the 
addition of potent immunosuppression could 
further abrogate this entire process. The pres-
ent studies evaluated combination therapy 
with FK-506 and SRI 63-441 on cardiac 
allograft survival in presensitized rats. 
MATERIALS AND METHODS 
Animals 
Commercially available inbred male Lewis (L) (RTll) 
and ACI (RTl') strain rats weighing 200 to 220 g were 
purchased from Harlan Sprague Dawley Co, Indianapo-
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lis. This strain combination was selected on the basis of a 
strong histoincompatibility to provide a reproducible and 
reliable model of hyperacute rejection. '4 
Surgical Procedures 
Skin grafting. Presensitization of L recipients was 
carried out under ether anesthesia by removing full-
thickness ventral abdominal skin from ACI donor rats. 14 
A 2.5-cm circular skin graft was transplanted to the 
dorsum of the L recipient and fastened with Clay Adams 
wound clips. Casting material was then applied for four 
days after the grafting procedure to immobilize the tissue. 
Grafts were evaluated visually for rejection. A second and 
third graft were placed at intervals of 14 days in a similar 
manner. 
Heterotopic heart transplantation. Heterotopic 
heart transplantation was performed 17 to 20 days after 
the third skin graft. 
The animals were anesthetized with 40 mg/kg sodium 
pentobar-bital intra peritoneally and supplemented with 
methoxyflurane. Surgical procedures for primarily vascu-
larized cardiac transplants in rats have been well 
described previously. IS Briefly, an end-to-side anastomo-
sis is performed between the donor and recipient aorta as 
well as the donor pulmonary artery and recipient vena 
cava. 
Impulses of the transplanted hearts were monitored 
every 30 minutes for the initial 15 hours and then twice 
daily thereafter by palpation through the recipient 
abdominal wall. Rejection was considered complete when 
there was no palpable contractions and confirmed visually 
at laparotomy and by histological evaluation. All experi-
mental animals were weighed daily. 
Drug Administration 
PAF antagonist. SRI 63-441 was supplied by Sandoz 
Research Institute (East Hanover, NJ). SRI 63-441 
(molecular weight [mol wtl, 662) was reconstituted in 
0.68% sodium acetate and 0.9% sodium chloride (pH 5.3) 
to a final concentration of 10 mg/mL and placed in a 
warm water bath (26 to 28OC) for five minutes. 
FK-506. Crystalline powder (mol wt, 882) was sup-
plied by Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan. 
A final concentration of 1.28 mg/mL was prepared in 
0.9% sodium chloride. 
Experimental Design 
Contemporaneous controls were performed for each 
experimental group. All recipients (L) animals were 
sensitized to donor (ACI) antigen. 
Experimental groups evaluated were as follows: group 
I, control (vehicle only); group 2, FK-506 alone; group 3, 
SRI 63-441 alone (l0 mg/kg); group 4, SRI 63-441 (lO 
mg/kg) plus FK-506; and group 5, SRI 63-441 (I5 
mg/kg) plus FK-506. 
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A single bolus injection of SRI 63-441 was adminis-
tered via the inferior vena cava four minutes before 
revascularization. 
FK-506 was administered at a dosage of 1.28 mg/kg/d 
for a duration of 14 days (or until rejection) by intramus-
cular injection commencing three days before transplan-
tation. 
Histology 
Tissues were formalin-fixed, paraffin-embedded, cut at 
3 /Lm, and stained with hematoxylin and eosin (H + E). 
Statistical Analysis 
Where available, mean survival times (MST) for 
experimental groups were compared by using the Wil-
coxon rank sum test. A P value of < .05 was considered 
statistically significant. 
It should be noted that in group 4 and 5 many of the 
animals were alive with functioning grafts at the time of 
manuscript preparation. 
RESULTS 
Survival 
The survival rates for the five groups evalu-
ated are listed in Table 1. Sensitized L control 
recipients consistently rejected ACI donor 
hearts in a hyperacute fashion (MST 0.27 ± 
0.09 days). Treatment of sensitized animals 
with SRI 63-441 alone as a single intravenous 
bolus of 10 mgjkg before revascularization 
resulted in a significant prolongation of car-
diac allograft survival (MST, 1.70 ± 0.66 
days; P < .003) when compared with control 
rats. 
Of even greater significance was the 
response in cardiac allograft survival observed 
when SRI 63-441 treatment (at two dosage 
levels) was combined with immunosuppres-
sion by FK-506 (groups 4 and 5). It is impor-
tant to note that five of 11 animals were still 
alive with functioning grafts at the time of 
preparation of this manuscript, with three 
animals approaching I-month survival. In 
fact, out of the 11 animals evaluated, one was 
killed at nine days for histological evaluation 
(Fig 1), and four grafts ceased to function at 
4, 8, 13, and 20 days after transplantation. 
These grafts demonstrated similar morpho-
logical features to those shown in Fig 1. One 
. 
. 
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Table 1 . The Effect of FK-506 and SRI 63-441 on Hyperacute Rejection of Rat Cardiac Allografts 
Group Treatment 
Control (vehicle on ly) 13 
2 FK-506 alone 5 
3 SRI 63-441 alone (10 mg/ kg) 5 
4 SRI 63-441 (10 mg/ kg) + 5 
FK-506 
5 SRI 63-441 ( 15 mg/kg) + 6 
FK-506 
"P < .003 as compared with group 1 (Mann-Whitney). 
tDied with a functioning graft. 
tKilled with a functioning graft for histological evaluation . 
Graft Survival 
(d) 
0002, 0005,0.007,0.01 , 
0 .02,0.08 , 0.15,0 .24, 
0,26,0.27 , 0.67,0.85, 
0 .97 
0 .06, 1.4, 2, > 3 , > 6 
0.06,1 . 13, 1. 19,2.19, 4.0 
4, 4 , t 13,21 , > 28 
8,9t,>4.> 10. >22,> 24 
MST '" SE 
0.27 ± 0,09 
1.70 ± 0 .66" 
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Fig 1. Myocardium (H + E; original magnification x 200) demonstrating slight mononuclear interstitial infiltrate 
and replacement by fibroblasts . This specimen is takan from a rat treated with SRI 63-441 and FK-506 and sacrificed 
at day 9 after transplantation with a functioning graft. It should be noted that a similar picture of minimal cellular 
rejection was evident in the grafts that ceased to function in similarly treated rats. 
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rat in group 4 died with a functioning graft 
four days after transplantation. This survival 
far exceeds allograft survival in nonsensitized 
recipients (6.3 ± 0.5 days). There was no 
significant change in weight in rats surviving 
long-term. 
Histologic Evaluation 
Tissue sections stained with H + E were 
reviewed without knowledge of treatment pro-
tocols. Morphological features interpreted as 
cardiac hyperacute rejection included exten-
sive interstitial hemorrhage, occlusion of ves-
sels by platelets, endothelial cell damage, and 
myocyte necrosis. Polymorphonuclear cell 
infiltration was not a constant feature. Sec-
tions exhibiting predominately a mononuclear 
cell infiltrate were interpreted as acute cellu-
lar rejection. Typically, there was much less 
interstitial hemorrhage and little or no plate-
let plugging of vessels noted. Myocyte de-
generation and fibroblast proliferation were 
frequently extensive. No overlap with hyper-
acute rejection was recognized. 
The native hearts of the animals in all 
groups were consistently without morphologi-
cal change. The extent and quality of the 
mononuclear infiltrate observed in the grafts 
of those animals treated with SRI 63-441 
alone and SRI 63-441 and FK-506 was quite 
different. The grafts of those animals treated 
with SRI 63-441 alone contained a more 
abundant mononuclear cell infiltrate, many of 
which exhibited features of blast formation. 
DISCUSSION 
The present study represents the first 
known report describing a therapeutic 
approach that completely overcomes the phe-
nomenon of experimental hyperacute rejec-
tion. We had already demonstrated that sig-
nificant abrogation of a very rapid and violent 
form of hyperacute rejection in a xenograft 
model could be achieved solely by the phar-
macological manipulation of the inflamma-
tory mediator response. 13 This relied on the 
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antagonism of PAF, perhaps the most impor-
tant inflammatory mediator to be nominated 
as a central candidate in the overall evolution 
of hyperacute rejection.9. 11 In a model of het-
erotopic cardiac transplantation into sensi-
tized rats, we were able to demonstrate that 
the phenomenon of hyperacute rejection, pre-
viously thought to be refractory and uncon-
trollable, could be converted into a potentially 
more manageable form of classic rejection by 
a single bolus administration of a PAF antag-
onist, SRI 63-441, before revascularization. 
Indeed, hearts in treated animals that ceased 
to function at two to four days after transplan-
tation demonstrated a very aggressive histo-
logical picture of acute cellular rejection with 
marked edema and extensive mononuclear 
cell infiltration (unpublished results). This 
suggested the prospect of adding classic 
immunosuppression in an attempt to over-
come the cellular rejection. 
It was clear that very potent immunosup-
pression would be required because the cellu-
lar rejection of hearts in the SRI 63-441-
treated animals was much more aggressive 
and was occurring much earlier than is 
usually seen in the same donor-recipient com-
bination without prior sensitization. This 
probably reflects the aggressive rejection of an 
organ made vulnerable by antibody attack. 
Other reports in this symposium have already 
demonstrated the potency and efficacy of FK-
506 as an immunosuppressant in standard 
transplant models. The combination of FK-
506 and SRI 63-441 treatment in this model 
of hyperacute cardiac rejection resulted in 
remarkable prolongation of graft survival in 
healthy animals. In fact, at the time of manu-
script preparation, 45% of the grafts were still 
surviving at various times after transplanta-
tion, with three grafts each approaching 30-
day survival. 
These studies provide further insight into 
the complex immunologic and inflammatory 
reactions involved in the process of hyperacute 
rejection. Moreover, we introduce a novel and 
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potentially effective therapeutic approach 
that relies on a combined attack on the very 
potent and unusually diverse spectrum of bio-
logic activities of a key inflammatory media-
tor as well as on a very aggressive form of 
classic cell-mediated rejection. 
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